Phosphorothioates, essential components of therapeutic oligonucleotides

Nucleic Acid Therapeutics

Volumn 24, Issue 6, 2014, Pages 374-387

  Eckstein, Fritz ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BACTERIAL DNA; CPG OLIGODEOXYNUCLEOTIDE; DNA POLYMERASE; FOMIVIRSEN; LOCKED NUCLEIC ACID; LONG UNTRANSLATED RNA; MESSENGER RNA; MICRORNA; MIPOMERSEN; NUCLEASE; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID; PHOSPHOROTHIOIC ACID; POLYNUCLEOTIDE; RNA POLYMERASE; SULFUR; TOLL LIKE RECEPTOR 9; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN BINDING; TRANSCRIPTION FACTOR;

CHEMICAL REACTION; CHEMICAL STRUCTURE; DIASTEREOISOMER; ENZYME INHIBITION; ENZYME STABILITY; GENE EXPRESSION; HUMAN; NONHUMAN; NUCLEIC ACID SYNTHESIS; REVIEW; STEREOCHEMISTRY; ANIMAL; CHEMISTRY; HISTORY; METABOLISM; MOUSE; RABBIT;

ANIMALS; HISTORY, 20TH CENTURY; HUMANS; MICE; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PROTEIN BINDING; RABBITS; TRANSCRIPTION FACTORS;

EID: 84915763945     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0506     Document Type: Review

References (127)

1. Piascik P. (1999) Fomiversen sodium approved to treat CMV retinits. J Am Pharm Assoc 39:84.
2. Perry CM and JAB Balfour. (1999). Fomivirsen. Drugs 57:375-380.
3. Raal FJ, RD Santos, DJ Blom, AD Marais, M-J Chang, WC Cromwell, RH Lachmann, D Gaudet, JL Tan, et al. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypocholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:998-1006.
4. Pauling L. The Nature of the Chemical Bond, 3rd ed. (1960) Cornell Univesity Press, Ithaca, NY, p. 200.
5. Liang C and LC Allen. (1987). Sulfur does not form double bonds in phosphorothioate anions. J Am Chem Soc 109:6449-6453.
6. Eckstein F. (1985). Nucleoside phosphorothioates. Annu Rev Biochem 54, 367-402.
7. Verma S and F Eckstein. (1998). Modified oligonucleotides: Synthesis and strategy for users. Annu Rev Biochem 67:99-134.
8. Eckstein F. (1966). Nucleoside phosphorothioates. J Am Chem Soc 88:4292-4294.
9. Bräutigam CA and TA Steitz. (1998). Structural principles for the inhibition of the 3-5 exonuclease activity of Escherichia coli DNA polymerase I by phosphorothioates. J Mol Biol 277:363-377.
10. Eckstein F and H Gindl. (1968). Uridin-2,3-O. Ocyclothiophosphat. Chem Ber 101:1670-1673.
11. Saenger W and F Eckstein. (1970). Stereochemistry of a substrate for pancreatic ribonuclease. Crystal and molecular structure of the triethylammonium salt of uridine 2, 3-O,Ocyclophosphorothioate. J Am Chem Soc 94:4712-4718.
12. Burgers PMJ and F Eckstein (1978). Absolute configuration of diastereomers of adenosine 5-O-(thiotriphosphate): Consequences for the stereochemistry of polymerisation by DNA-dependent RNA-polymerase from E. coli. Proc Natl Acad Sci (USA) 75:4798-4800.
13. Bartlett PA and F Eckstein. (1982). Stereochemical course of polymerisation catalysed by Avian Myeloblastosis Virus reverse transcriptase. J Biol Chem 257:8879-8884.
14. Romaniuk PJ and F Eckstein. (1982). A study of the mechanism of T4 DNA polymerase with diastereomeric phosphorothioate analogues of deoxyadenosine triphosphate. J Biol Chem 257:7684-7688.
15. Connolly BA, BV Potter, F Eckstein, A Pingoud and L Grotjahn. (1984). Synthesis and characterization of an octanucleotide containing the EcoRI recognition sequence with a phosphorothioate group at the cleavage site. Biochemistry 23:3443-3453.
16. Burgers PMJ and F Eckstein. (1978). Synthesis of dinucleoside monophosphorothioates via addition of sulfur to phosphite triesters. Tetrahedron Lett 3835-3838.
17. Cruse WBT, SA Salisbury, T Brown, R Cosstick, F Eckstein and O Kennard. (1986). Chiral phosphorothioate analogues of B-DNA: The crystal structure of Rp d[Gp(S)CpGp(S)C]. J Mol Biol 192:891-905.
18. Usher DA, ID Richardson and F Eckstein. (1970). Absolute stereochemistry of the second step of ribonuclease action. Nature 228:663-665.
19. Usher DA, ES Erenrich and F Eckstein. (1972) Geometry of the first step in the action of ribonuclease A Proc Nat Acad Sci (USA) 69:115-118.
20. Eckstein F. , W Saenger and D Suck. (1972). Stereochemistry of the transesterification step of pancreatic ribonuclease. Biochem Biphys Res Com 46:964-971.
21. Griffiths AD, BVL Potter and IC Eperon. (1987). Nucleic Acids Res 15:4245-4162.
22. Burgers PMJ and F Eckstein. (1979). A study of the mechanism of DNA polymerase I from Escherichia coli with diastereomeric phosphorothioate analogs of deoxyadenosine triphosphate. J Biol Chem 254:6889-6983.
23. Goody R and F Eckstein. (1970). Thiophosphate analogs of nucleoside di-and triphosphates. JAm Chem Soc 93:6252-6257.
24. Gratecos D and EH Fischer. (1974). Adenosine 5-O-(3-thiotriphosphate) in the control of phosphorylase activity. Biochem Biophys Com 58:960-967.
25. Hiriyanna KT, D Baedke, K-H Baek, BA Forney, G Kordiyak and TS Ingebritsen. (1994). Thiophosphorylated substrate analogs are potent active site-directed inhibitors of protein-tyrosine phosphatases. Anal Biochem 223:51-58.
26. Jeong S and TT Nikiforov. (1999). Kinase assay based on thiophosphorylation and biotinylation. BioTechniques 27, 1232-1238.
27. Garber KCA and EE Carlson. (2013). Thiol-ene enabled detection of thiphosphorylated kinase substrates. ACS Chem Biol 8:1671-1676.
28. Allen JJ, M Li, CS Brinkworth, JL Paulson, D Wang, A Huebner, W-H Chou, RJ Davis, AL Burlingame, et al. (2007) A semisynthetic epitope for kinase substrates. Nat Methods 4:511-516.
29. Spitzer S and F Eckstein. (1988). Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides. Nucleic Acids Res 16:11691-11704.
30. Potter BVL, PJ Romaniuk and F Eckstein. (1983a). Stereochemical course of DNA hydrolysis by nuclease S1. J Biol Chem 258:1758-1760.
31. Potter BVL , BA Connolly and F Eckstein. (1983b) Synthesis and configurational analysis of a dinucleotide phosphate isotopically chiral at phosphorus. Stereochemical course of Penicillium citrum nuclease P1 reaction. Biochem 22:1369-1377.
32. Steitz TA and JA Steitz. (1993). A general two-metal ion mechanism for catalytic RNA. Proc Natl Acad Sci (USA) 90:6498-6502.
33. Thang YL, F Hollfelder, SJ Gordon, L Chen, Y-F Keng, L Wu, Herschlag D. and Z-Y Zhang. (1999). Impaired transition state complementarity in the hydrolysis of Oarylphosphorothioates by protein-tyrosine phosphatases. Biochemistry 38:12111-12123.
34. Vosberg H-P and F Eckstein. (1977). Incorporation of phosphorothioate groups into fd and jX174 DNA. Biochem 16:3633-3640.
35. Taylor JW, W Schmidt, R Cosstick, A Okruszek and F Eckstein. (1985). The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare nicked DNA. Nucleic Acids Res 13:8749-8764.
36. Sayers JR, DB Olsen and F Eckstein. (1989). Inhibition of restriction endonuclease hydrolysis by phosphorothioatecontaining DNA. Nucleic Acids Res 17:9495-9496.
37. Ueda T, H Tohda, N Chikazumi, F Eckstein and K Watanabe. (1991). Phosphorothioate-containing RNAs show mRNA activity in the prokaryotic translation systems in vitro. Nucleic Acids Res 19:547-552.
38. Iyengar R, F Eckstein and PA Frey. (1984). Phosphorus-oxygen bond order in adenosine 5-O-phosphorothioate dianion. J AmChem Soc 106:8309-8310.
39. Frey PA and RD Sammons. (1985). Bond order and charge localization in nucleoside phosphororthioates. Science 228:541-545.
40. Baraniak J and PA Frey. (1988). Effect of ion pairing on bond order and charge localization in alkyl phosphorothioates. J Am Chem Soc 110:4059-4060.
41. Pearson RG. (1966). Acids and bases. Science 151:172-177.
42. Jaffe EK, and M Cohen. (1978). Divalent cation-dependent sterespecificity of adenosine 5-O-(2-thiotriphosphate) in the hexokinase and pyruvate kinase reactions. J Biol Chem 253:4823-4825.
43. Pecoraro VL, JD Hermes and WW Cleland. (1984). Stability constants of Mg2+ and Cd2+ complexes of adenine nucleotides and thionucleotides and rate constants for formation and dissociation of MgATP and MgADP. Biochemistry 23:5262-5271.
44. Frederiksen J. K. , N-S Li, R Das, D Herschlag and JA Piccirilli. (2012). Metal-ion rescue revisited: Biochemical detection of site-bound metal ions important for RNA folding. RNA 18:1123-1141.
45. Fica SM, N Tuttle, T Novak, N-S Li, J Lu, P Koodathingal, Q Dai, JP Staley and JA Piccirilli. (2013). RNA catalyses nuclear pre-mRNA splicing. Nature 503:229-234.
46. Gaynor JW and R Cosstick. (2008). Synthesis, properties, and application of nucleic acids containing phosphorothiolate linkages. Curr Org Chem 12:291-308.
47. Li N-S, JK Frederiksen and JA Piccirilli. (2011). Synthesis, properties, and applications of oligonucleotides containing an RNA dinucleotide phosphorothiolate linkage. Acc Chem Res 44:1257-1269.
48. Cosstick R, LW Mclaughlin and F Eckstein. (1984). Fluorescent labelling of RNA and oligodeoxynucleotides using T4 RNA ligase. Nucleic Acids Res 12:1791-1810.
49. Burgin AB and NR Pace. (1990). Mapping the active site of ribonuclease P RNA using a substrate containing a photoaffinity agent. EMBO J 9:4111-4118.
50. Wang JF, WD Downs and TR Cech. (1993) m Movement of the guide sequence during RNA catalysis by a group I ribozyme. Science 260:504-508.
51. Musier-Forsyth K. and P Schimmel. (1994). Acceptor helix interactions in a class II tRNA synthetase: Photoaffinity cross-linking of an RNA miniduplex substrate. Biochemistry 3:773-779.
52. Konarska M. (1999). Site-specific derivatization of RNA with photocrosslinkable groups. Methods 18:22-28.
53. Gish G and F Eckstein. (1988). DNA and RNA sequence determination based on phosphorothioate chemisttry. Science 240:15201522.
54. Nakamaye KL, G Gish, F Eckstein and Vosberg H.-P. (1988). Direct sequencing of polymerase chain reaction amplified DNA fragments through the incorporation of deoxynucleoside alpha-thiotriphosphates. Nucleic Acids Res 16:9947.
55. Strobel SA and K Shetty. (1997). Defining the chemical groups essential for Tetrahymena group I intron function by nucleotide analog interference mapping. Proc Natl Acad Sci (USA) 94:2903-2908.
56. Cao B, C Chen, MS Demott, Q Cheng, TA Clark, X Xiong, X Zheng, V Butty, SS Levine, et al. (2014). Genomic mappping of phosphorothioates reveals partial modification of short consensus sequences. Nat Commun 5:3951. [Epub ahead of print]; DOI: 10. 1038/ncomms4951.
57. Matzura H and F Eckstein. (1968). A polyribonucleotide containing alternating P = 0 and P = S linkages. Eur J Biochem 3:448-452.
58. Eckstein F and H Gindl. (1969). Polyribonucleotides containing a thiophosphate backbone. FEBS Lett 2:262-264.
59. De Clercq E, F Eckstein and TC Merigan. (1969). Interferon induction increased through chemical modification of a synthetic polyribonucleotide. Science 165:1137-1139.
60. De Clercq E, F Eckstein, H Sternbach and TC Merigan. (1970). The antiviral activity of thiophosphate-substituted polyribonucleotides in vitro and in vivo. Virology 42:421-428.
61. Zamecnik PC and ML Stephenson. (1978. ) Inhibition of Rouse sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Nat Acad Sci (USA) 75:280-284.
62. Matsukura M, K Shinozuka, G Zon, H Mitsuya, M Reitz, JS Cohen, and S Broder. (1987). Phosphorothioate analogues of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Nat Acad Sci (USA) 84:7706-7710.
63. Agrawal S, J Goodchild, MP Civeira, AH Thornton, PS Sarin, and PC Zamecnik. (1988). Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Nat Acad Sci (USA) 85:7079-7083.
64. Matsukura M, G Zon, M Robert-Guroff, CA Stein, H Mitsuya, F Wong-Staal, JS Cohen and S Broder. (1989). Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev(art/trs) in chronically infected cells. Proc NatAcad Sci (USA) 86:4244-4248.
65. Stec WJ, G Zon, W Ega and B Stec. (1984). Automated solid-phase synthesis, separation and stereochemistry of phosphorothioate analogues of oligodeoxynucleotides. J Am Chem Soc106:6077-6089.
66. Walder RY and JA Walder. (1988). Role of RNase in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci (USA) 85:5011-5015.
67. Furdon PJ, Z Dominski and R Kole. (1989). RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res 17:9193-9200.
68. Stec WJ, B Karwowski, M Boczkowska, P Guga, M Koziolkiewicz, M Sochaki, MW Wbeczorek and J Blaszczyk. (1998). Deoxyribonucleoside 3-O-(2-thio-and 2-oxo-''spiro''-4,4-pentamethylene-1,2,3-oxathiaphospholane)s: Monomers for stereocontrolled synthesis of oligo(deoxyribonucleoside phosphorothioate)s and chimeric PS/PO oligonucleotides. J Am Chem Soc 120:7156-7167.
69. Oka N, M Yamamoto, T Sato and T Wada,. (2008). Solidphase synthesis of stereoregular oligodeoxyribonucleoside phosphorothioates using bicyclic oxazaphospholidine derivatives as monomer units. J Am Chem Soc 130:16031-16037.
70. Boczkowska M, P Guga and W Stec. (2002). Stereodefined Phosphorothioate Analogues of DNA: Relative Thermodynamic Stability of the Model PS-DNA/DNA and PS-DNA/RNA Complexes. Biochemistry 41:12483-12487.
71. Koziolkiewicz M, A Krakowiak, M Kwinkowski, M Boczkowska and WJ Stec. (1995). Stereodifferentiation- the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of RNase H. Nucleic Acids Res 23:5000-5005.
72. Stec WJ, CS Cierniewski, A Okruszek, A Kobylanska, Z Pawlowska, M Koziolkiewicz, E Pluskota, A Maciaszek, B Rebowska and M Stasiak. (1997). Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: Proof of sequence specificity in cell culture and in vivo rat experiments. Antisense Nucleic Acid Drug Dev 7:567-573.
73. Krieg AM, P Guga and W Stec. (2003). P-Chirality-Dependent Immune Activation by Phosphorothioate CpG Oligodeoxynucleotides. Oligonucleotides 13:491-499.
74. Lok C-N, E Viazokina, K-L Min, E Nagy, CJ Wilds, MJ Damha and MA Parniak. (2002). Potent gene-specific inhibitory properties of mixed-backbone antisense oligoncleotides comprised of 2-doxy-2-fluoro-D-arabinose and 2-deoxyribose nucleotides. Biochem 41:3457-3467.
75. Monia BP, EA Lesnik, C Gonzales, WF Lima, D Mcgee, C. J. Guinosso, AM Awasaki, PD Cook and SM Freier. (1993). Evaluation of 2-modified oligonucleotides containing 2-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268:14514-14522.
76. Stanton R, S Sciabola, C Salatto, Y Wenig, D Moshinsky, J Little, E Walters, J Kreeger, D Dimattia, et al. (2012). Chemical modification study of antisense gapmers. Nucleic Acids Ther 22:344-359.
77. Dias N and CA Stein. (2002) Antisense oligonucleotides: Basic concepts and mechanisms. Mol Cancer Ther 1:347-355.
78. Crooke ST ed. Antisense Drug Technology, Principles, Strategies, and Applications. Second edition. (2008) CRC Press, Boca Raton, FL.
79. Bennett CF and EE Swayze. (2010). RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmcol Toxicol 50:259-293.
80. Lightfoot HL and J Hall. (2012). Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res 21, 10585-10595.
81. Ulitsky I, A Shkumatava, CH Jan, H Sive and DP Bartel. (2011). Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution. Cell 147:1537-1550.
82. Modarresi F, MA Faghili, MA Lopez-Toledano, RP Fatemi, M Magistri, SP Brothers, MP Van Der Bru. and C Wahlested. (2012). Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol 30:453-459.
83. Hu J, J Liu, KJ Naryanannair, JG Lackey, S Kuchimanchi, KG Rajeev, M Manoharan, EE Swayze, WF Lima, et al. (2014). Allele-selective inhibition of mutant Atrophin-1 expression by duplex and single-stranded RNAs. Biochem 53:4510-4518.
84. Lima WF, TP Prakash, HM Murray, GA Kinberger, W Li, AE Chappell, CS Li, SF Murray, H Gaus, et al. (2012). Single-stranded siRNAs activate RNAi in animals. Cell 150:883-894.
85. You D, H Pendergraff, J Liu, HB Kordasiewicz, DW Cleveland, ES Swayze, WF Lima, ST Crooke, TP Prakash and DR Corey. (2012). Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant Huntingtin expression. Cell 150:895-908.
86. Liu J, D Yu, Y Aiba, H Pendergraff, EE Swayze,WLima, J Hu, TP Prakash and DR Corey. ss-siRNAs allele selectively inhibit taxin-3 expression: multiple mechanisms for an alternative gene silencing strategy. Nucleic Acids Res 41:9570-9583.
87. Hu J, J Liu, D Yu, Y Aiba, S Lee, H Pendergraff, J Boubaker, JW Artates, C Lagier-Tourenne, et al. (2014). Exploring the Effect of Sequence Length and Composition on Allele-Selective Inhibition of Human Huntingtin Expression by Single-Stranded Silencing RNA. Nucleic Acid Ther 24:199-209.
88. Aartsma-Rus A. (2014). Antisense-mediated exon skipping: Networking to meet opportunities and to overcome challenges. Nucleic Acid Ther 24:1-3.
89. Disterer P, A Kryczka, Y Liu, YE Badi, JJ Wong, JS Owen and B Khono. (2014). Development of therapeutic splice-switching oligonucleotides. Hum Gene Ther 25: 5. 87-598.
90. Järver P, L O'donnovan and M Gait. (2014). A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther 24:37-47.
91. Kole R, AR Krainer and S Altman. (2012). RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125-140.
92. Goemans NM, M Tulinius, JT Van Den Akker, BE Burm, PF Ekhart, N Heuvelmans, T Holling, AA Janson, GJ Platenburg, et al. (2011). Systemic administration of PRO051 in Duchenne's Muscular Dystrophy. N Engl J Med 364:1513-1522.
93. Porensky PN and HM Burghes. (2013) Antisense oligonucleotides for the treatment of spinal muscular atrophy. Human Gene Ther 24:489-498.
94. Hua Y, K Sahashi, G Hung, F Rigo, MA Passini, CF Bennett and AR Krainer. (2010). Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Gen Devel 24:1634-1644.
95. Rigo F, Y Hua, SJ Chun, TP Prakash, AR Krainer and CF Bennett. (2012). Synthetic olgonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nat Chem Biol 8:555-561.
96. Bartel DP. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
97. Krützfeldt J, S Kuwajima, R Braich, KG Ajeev, J Pena, T Tuschl, M Manoharan and M Stoffel. (2007). Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 35:2885-2892.
98. Elmen J, M Lindow, S Schütz, M Lawrence, A Pettri, S Obad, M Lindholm, M Edtjärn, HF Hansen, et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452:896-900.
99. Esau C, S Davis, SF Murray, XX Yu, SK Pandey, M Pear, L Watts, SL Booten, M Graham, et al. (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3:87-98.
100. Juliano RL, X Ming, K Carver and B Laing. (2014). Cellular uptake and intracellular trafficking of oligonucleotides: Implications for oligonucleotide pharmacology. Nucleic Acid Ther 24:101-113.
101. Geary RS, TA Watanabe, L Truong, S Freier, EA Lesnik, NB Sioufi, H Sasmor, M Manoharan and AA Levin. (2001). Pharmacokinetic properties of 2-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296:890-897.
102. Hung G, X Xiao, R Peralta, G Bhattacharjee, S Murray, D Norris, S Guo, and BP Monia. (2013). Characterisation of target mRNA reduction through in situ RNA hybridisation in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther 23:369-378.
103. Koller E, TS Vincent, A Chappell, S De, M Manoharan. and CF Bennett. (2011). Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39:4795-4807.
104. Stein CA, JB Hansen, J Lai, S Wu, A Voskresenskiy, A Hog, J Worm, M Hedtjarn, N Souleimanian, et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38: e3.
105. Souleimanian N, GF Deleavey, H Soifer, S Wang, KM Tieman, J Damha, and A Stein. (2012). Antisense 2-deoxy-2-fluoroarabinonucleic acids (2-F-ANAs) antisense oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids. Mol Ther Nucleic Acids 1:e43; 10. 1038.
106. Juliano RL. (2005). Peptide-oligonucleotide conjugatesfor the delivery of antisense and siRNA. Curr Opin Mel Ther 7:132-136.
107. Jirka, MG, H Hemskerk, CL Tanganyika-De Winter, D Muilwijk, KH Pang, PC De Visser, A Janson, TG Karnaoukh, R Veremue, et al. (2014). Peptide conjugation of 2-O-methyl phosphorothioate antisense olgonucleotides enhances cardiac uptake and exon skipping in mdx mice. Nucleic Acid Ther 24:25-36.
108. Manoharan M. (2013). RNAi therapeutics using GalNAcsiRNA conjugate delivery platform: New era of oligonucleotides. Presented at Oligonucleotide Therapeutics Society Ninth Annual Meeting, Naples, Italy, October 6-8, 2013.
109. Prakash TP, MJ Graham, J Yu, R Carty, A Low, A Chappel, K Schmidt, C Zao, M Aghajan, . (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res 42:8796-4807.
110. Bhat B, S Neben, J Tay, K Liu, N Chau, D Hogan, D MacKenna, N Gibson. (2014). RG-101, a GalNACconjugated anti-miR employing a unique mechanism of action by targeting host factor microRNA-122 (miR-122), demonstrates potent activity and reduction of HCV in preclinical studies. Hepatology 58:1377A-1395A.
111. Bielinska A, RA Shivdasani, L Zhang and GJ Nabel. (1990). Regulation of gene expression with doublestranded phosphorothioate oligonucleotides. Science 250: 997-1000.
112. Osako MK, H Nakagami and R Morishita. (2012). Modification of decoy oligonucleotides to achieve the stability and therapeutic efficacy. Curr Top Med Chem 12:1603-1607.
113. Luehrmann A, T Tschernig, H Von Der Leyen, M Hecker, R Pabst and AH Wagner. (2010). Decoy oligodeoxynucleotide against STAT transcription factors decreases allergic inflammation in a rat asthma model. Exp Lung Res 36:85-93.
114. Gryaznov SM (2010). Oligonucleotide N3-P5 phosphoramidates and thio-phosphoramidates as potential therapeutic agents. Chem Biodivers 7:477-493.
115. Krieg AM, AK Yi, S Matson, TJ Waldtschmidt, GG Bishop, R Teasdale, GA Koretzky and DM Klinman. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 74, 546-549.
116. Krieg AM. (2012). CpG still rocks! Update on an accidental drug. Nucleic Acids Therapeutics 22:77-89.
117. Kandimalla ER, L Bhagat, D Wang, D Yu, T Sullivan, NL Monica. and S Agrawal. (2013). Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res 41: 3947-3961.
118. Zhang Q, DMS Hossein, S Nechaev, A Kozlowska, W Zhang, Y Liu, CM Kowolik, P Swiderski, JJ Rossi, et al. (2013). TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood 121:1304-1315.
119. Kunkel TA, F Eckstein, AS Mildvan, RM Koplitz, and LA Loeb. (1981). Deoxynucleoside [1-thio] triphosphates prevent proofreading during in vitro DNA synthesis. Proc Natl Acad Sci (USA) 78:6734-6738.
120. Skerra A. (1992). Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerases with proofreading activity. Nucleic Acids Res 20:3551-3554.
121. Hutchinson III CA, HO Smith, C Pfannkoch and JC Venter. (2005). Cell-free cloning using j29 DNA polymerase. Proc Natl Acad Sci (USA) 102:17322-17336.
122. Valouev A, J Ichikawa, T Tonthat, J Stuat, S Ranade, S. , H Peckham, K Zeng, JA Malek, G Costa, et al. (2008). A high-resolution, nucleosome position map of C. elegans reveals a lack of universal sequence-directed positioning. Genome Res 18:1051-1063.
123. Ronaghi M, M Uhlen and P Nyren. (1998). A sequencing method based on real-time pyrophosphate. Science 281:363-364.
124. Lianrong W, S Chen, T Xu, K Taghizadeh, JS Wishnok, X Zhou, D You Z Deng and PC Dedon. (2007). Phosphorothioation of DNA in bacteria by dnd genes. Nat Chem Biol 3:709-710.
125. Xie X, J Liang, T Pu, F Xu, F Yao, Y Yang, Y-L Zhao, D You, X Zhou, Z Deng and Z Wang. (2012). Phosphorothioate DNA as an antioxidant in bacteria. Nucleic Acids Res 40:9115-9124.
126. Xu T, F Yao, X Zhou, Z Deng and D You. (2010). A novel host specific restriction system associated with DNA backbone S-modification in Salmonella. Nucleic Acids Res 38:7133-7141.
127. Cao B, Q Cheng, C Gu, F Yao, MS DeMott, X Zheng, Z Deng, PC Dedon and D You. (2014). Pathological phenotypes and in vivo DNA cleavage by unrestrained activity of a phosphorothioate-based restriction system in Salmonella. Mol Microbiol 93:776-785.